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Background: The extensive use of computed tomography (CT) after acute head 
injury is costly and carries potential iatrogenic risk. This systematic review examined 
the usefulness of blood-based glial fibrillary acidic protein (GFAP) for predicting acute 
trauma-related CT-positive intracranial lesions following head trauma. The main objective 
was to summarize the current evidence on blood-based GFAP as a potential screening 
test for acute CT-positive intracranial lesions following head trauma.
methods: We screened MEDLINE, EMBASE, PsychInfo, CINAHL, Web of Science, the 
Cochrane Database, Scopus, Clinical Trials, OpenGrey, ResearchGate, and the refer-
ence lists of eligible publications for original contributions published between January 
1980 and January 2017. Eligibility criteria included: (i) population: human head and 
brain injuries of all severities and ages; (ii) intervention: blood-based GFAP measurement 
≤24 h post-injury; and (iii) outcome: acute traumatic lesion on non-contrast head CT 
≤24 h post-injury. Three authors completed the publication screening, data extraction, 
and quality assessment of eligible articles.
Results: The initial search identified 4,706 articles, with 51 eligible for subsequent 
full-text assessment. Twenty-seven articles were ultimately included. Twenty-four (89%) 
studies reported a positive association between GFAP level and acute trauma-related 
intracranial lesions on head CT. The area under the receiver operating characteristic 
curve for GFAP prediction of intracranial pathology ranged from 0.74 to 0.98 indicat-
ing good to excellent discrimination. GFAP seemed to discriminate mass lesions and 
diffuse injury, with mass lesions having significantly higher GFAP levels. There was 
considerable variability between the measured GFAP averages between studies and 
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assays. No well-designed diagnostic studies with specific GFAP cutoff values predictive 
of acute traumatic intracranial lesions have been published.
conclusion: Intracranial CT-positive trauma lesions were associated with elevated GFAP 
levels in the majority of studies. Methodological heterogeneity in GFAP assessments and 
the lack of well-designed diagnostic studies with commercially validated GFAP platforms 
hinder the level of evidence, and variability in levels of GFAP with no clearly established 
cutoff for abnormality limit the clinical usefulness of the biomarker. However, blood-
based GFAP holds promise as a means of screening for acute traumatic CT-positive 
lesion following head trauma.
Keywords: brain injury, head injury, computed tomography, glial fibrillary acidic protein, emergency departments
iNtRODUctiON
Rationale
Since the inception of computed tomography (CT) in the 1970s, 
its use has increased rapidly (1). Between 1980 and 2017, the 
number of annual CT scans in the United States has increased 
from 3 to 62 million (2) with the head being the most commonly 
imaged area. In modern medicine, non-contrast head CT is the 
gold standard for identifying significant intracranial injury in 
an emergency department setting (3). Numerous decision rules 
[e.g., New Orleans Criteria (4), Canadian CT Head Rule (5)] 
have been developed in order to focus CT imaging on patients 
with the greatest risk for clinically significant intracranial injury. 
However, despite these decision algorithms, a considerable 
number of trauma head CT scans are performed unnecessar-
ily (1, 6). Almost 80% find no evidence of acute intracranial 
pathology (7).
There is a non-trivial iatrogenic risk associated with CT 
scanning, mainly for radiation-induced neoplasia. One head 
CT significantly increases the risk of subsequent cancer with 
subsequent CTs conferring additive vulnerability (6, 8). Further, 
considering the economic cost associated with CT proliferation, 
judicious use of this imaging modality is important. A growing 
body of evidence has shown that some blood-based brain trauma 
biomarkers could aid in predicting which patients will have acute 
intracranial abnormalities, thus possibly reducing unnecessary 
head CT scanning (9, 10). Glial fibrillary acidic protein (GFAP) 
is one of these biomarkers (9, 10).
For several decades, S100B has been investigated as a blood-
based marker of brain damage (11). Since the publication of the 
most recent Scandinavian guidelines for head injury management 
(12), S100B has been adopted into clinical use mainly in some 
Nordic countries. According to the guidelines, S100B can be 
used to substitute head CT scanning in isolated mild head injury 
patients, who have a low risk for intracranial hemorrhage and are 
seen within 6 h of injury. Two recent publications have shown 
that S100B in the context of the Scandinavian guidelines is a safe 
and cost-effective means of reducing the number of unnecessary 
CTs in head trauma (13, 14). The clear caveat and applicability-
weakening factor of S100B is the sensitivity to extracranial 
injuries and a short metabolic half-life (11). Theoretically, GFAP 
is superior to S100B with a more brain injury-specific profile and 
a longer half-life (15–17).
A substantial body of literature suggests that serum GFAP 
elevations are associated with acute brain pathology, as evidenced 
by head CT, across the spectrum of brain injury severity (17–22). 
Increases in serum levels are detectable within hours of injury 
and stay elevated for days, a temporal profile that makes GFAP 
detection potentially very practical and useful in the emergency 
setting (22, 23).
Objectives
We conducted a systematic review of the usefulness of blood-
based GFAP for predicting acute trauma-related CT-positive 
intracranial lesions. The main objective was to summarize the 
current evidence on blood-based GFAP as a potential screening 
test for acute CT-positive intracranial lesions following head 
trauma. Our secondary objective was to examine whether or not 
GFAP was clearly associated with intracranial lesions in patients 
with mild traumatic brain injury (TBI).
Research Question
Is increased blood-based GFAP consistently associated with 
acute (within 24 h post-injury) CT-detectible intracranial trauma 
lesions following head injury?
metHODS
Participants
Eligibility criteria included: (i) population: human head and brain 
injuries of all severities and age groups; (ii) intervention: blood-
based GFAP measurement ≤24 h post-injury; and (iii) outcome: 
acute traumatic lesion on non-contrast head CT ≤24  h post-
injury. We focused on emergency management and, therefore, 
applied the time cutoff of 24 h and examined only blood-based 
GFAP.
Systematic Review Protocol
The review was registered with PROSPERO (registration number: 
CRD42016049452) and adhered to the PRISMA guidelines (24).
Search Strategy
We screened MEDLINE, EMBASE, PsychInfo, CINAHL, Web 
of Science, the Cochrane Database, Scopus, Clinical Trials, 
OpenGrey, ResearchGate, and the reference lists of eligible 
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of Evidence-based Medicine (26) and GRADE rankings (27). 
To obtain and confirm missing data (e.g., on study methodology), 
the investigators of the included publications were contacted 
by email. Some publications were comprised of overlapping 
samples, which was acknowledged in the qualitative synthesis. 
We defined head injury of any severity as the labeling criteria for 
a case. For example, some studies classified head trauma patients 
with negative CT scans as “controls.” For this systematic review, 
these patients were assigned as head trauma cases instead of 
controls. Results from adult and pediatric studies are reported 
separately.
ReSULtS
Study Selection and characteristics
The PRISMA flow chart is presented in Figure 1. A total of 27 
articles [adult studies: 22 (81%), and pediatric studies: 5 (19%)] 
were included. Table 1 summarizes the main characteristics of 
the included studies.
For this review, we re-classified seven (19%) studies as cohort 
studies although the original authors named those study designs 
case–control (46). The investigators in 17 (63%) publications did 
not explicitly report the study design. Of the included studies, 
13 (48%) were case–control and 14 (52%) cohort studies. All of 
the included studies were observational; none of the studies had 
a diagnostic test design (the accuracy of exact GFAP levels in 
distinguishing CT-positives from CT-negatives). The majority of 
the studies were conducted in trauma centers in the United States.
Patient Demographics and acute 
traumatic Lesions
A total of 3,549 participants (68% males) with mild to severe TBI 
were enrolled in the included studies with individual sample sizes 
varying between 27 and 325. Control sample sizes varied between 
13 and 259 participants, for a sum total of 1,522, of which 54% were 
males. Orthopedic trauma patients and healthy volunteers were 
the most commonly enrolled controls; other controls included 
blood donors and also paid volunteers. The age distribution of 
the participants was as follows: adult TBI = 15–91 years, pediatric 
TBI =  0–21  years, adult controls =  18–83  years, and pediatric 
controls = 0–21 years. Depending on the study, 9–100% of the 
patients with TBI had acute traumatic lesions on head CT. The 
Marshall classification (47) was the most commonly used head 
CT grading system (12 studies, 44%). Many studies reported only 
gross categories of the traumatic intracranial lesion (i.e., subdural 
hematoma, contusion, subarachnoid hemorrhage) or only 
binary CT outcomes (i.e., “positive” or “negative”). A consider-
able number of studies did not explicitly specify the subtypes of 
abnormalities that were considered as acute traumatic CT lesions 
(16 studies, 59%).
analytical Platforms
The analytical platforms used to measure GFAP were diverse, 
with 10 different methods employed across the 27 studies. 
The sandwich enzyme-linked immunosorbent assay (ELISA) 
manufactured by Banyan Biomarkers (Banyan Biomarkers, 
publications for original contributions published between Jan-
uary 1, 1980, and October 12, 2016. In order to make the review 
more comprehensive, we updated the literature search on the 
10th of February 2017, and thus included original publica-
tions published between January 1, 1980 and January 31, 2017. 
A senior research librarian performed the literature search. 
The key search terms included: head injur*; head trauma; brain 
injur*; brain trauma; brain damage; brain contusion*; brain 
laceration*; brain hemorrhage*; concussion*; MTBI*; TBI*; 
craniocerebral injur*; craniocerebral trauma; craniocerebral 
damage; intracranial hemorrhage*; intracranial hematoma; 
intracranial lesion*; intracranial abnormalit*; intracerebral 
hemorrhage, traumatic; hematoma, subdural, acute; subdural 
hematoma; hematoma, epidural, cranial; epidural hematoma; 
cerebral hemorrhage, traumatic; cerebral hematoma, trau-
matic; subarachnoid hemorrhage; diffuse axonal injur*; glial 
fibrillary acidic protein*; astroprotein; glial fibrillary acid pro-
tein; glial intermediate filament protein; GFA-protein; GFAP; 
and GFAP-BDP. The detailed search strategy is presented in an 
online supplement (Appendix S1 in Supplementary Material). 
We included only studies published in English.
Screening and eligibility
The web-based reference management program Mendeley© 
(Mendeley Ltd., London, UK) was used for publication screen-
ing. Before uploading the references to Mendeley©, duplicate 
publications (duplicate exclusion: n = 2,232; included for screen-
ing: n =  2,474) were excluded by our librarian. Three authors 
(Teemu M. Luoto, Rahul Raj, and Jussi P. Posti; hereafter assessing 
authors) completed the publication screening, data extraction, 
and quality assessment of eligible articles. Each of the included 
publications (n = 2,474) was initially screened for eligibility based 
on the title and abstract by two of these assessing authors. After 
initial screening, 2,423 publications were excluded because they 
did not fulfill the aforementioned eligibility criteria. Two assess-
ing authors also independently reviewed the full-text versions 
of a subset of primarily eligible articles (n = 51). Conflicts over 
inclusion were resolved by involving the third assessor.
Data extraction and analysis
Teemu M. Luoto, Rahul Raj, and Jussi P. Posti completed the 
publication screening, data extraction, and quality assessment of 
eligible articles. The data extraction form included the following 
variables: study design and setting, study country and number 
of sites used, method of GFAP analytics, head CT findings 
(gradings and percentage of abnormal findings), time intervals 
between injury and CT/GFAP assessments, extracranial injuries, 
samples sizes (TBI patient and/or controls), gender and age dis-
tributions, GFAP concentrations, and results of relevant statisti-
cal tests. All the extracted data were collected on a group level, 
no individual case level data were available. On an individual 
article level, two of the assessing authors extracted data inde-
pendently, and the third reviewed and verified these extraction 
results. Conflicts over results were resolved by consensus. The 
scientific quality (including potential sources of bias) of each 
article was evaluated with the Newcastle–Ottawa Scale (25). 
The level of evidence was rated according to the Oxford Center 
FiGURe 1 | PRISMA flow chart.
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Inc., Alachua, FL, USA) was the most frequently used platform 
(10 studies, 37%). The second most used (7 studies, 26%) plat-
form was BioVendor (BioVendor, Heidelberg, Germany). In two 
studies, the precise analytic GFAP platform was not stated (con-
sidered as two different individual platforms that are not other-
wise specified in this review). The analytic methods are shown 
in Table 1. Most studies used venous blood as their source for 
GFAP measurement, although two studies used arterial samples 
(note: an assumption of venous sampling was made if there 
was no direct reference to arterial sampling). Four studies out 
of the 10 that used the Banyan Biomarkers assay also analyzed 
GFAP breakdown products in addition to native GFAP.
Synthesized Findings
There was considerable variability in GFAP levels within the 
same platform and between platforms (e.g., Banyan Biomarkers 
vs. BioVendor). For controls (orthopedic injuries and/or healthy 
participants), the reported GFAP levels varied considerably 
across studies (adult: range of means =  0.0015–0.057  ng/mL, 
range of medians =  0–0.0008  ng/mL; and pediatric: range of 
medians = 0.01–0.03 ng/mL). Between studies, orthopedic con-
trols did not appear to show consistently higher GFAP levels com-
pared to healthy controls. There was only one study that reported 
results for both non-injured controls and non-TBI trauma 
controls. In this particular study (32), trauma controls had higher 
GFAP levels than uninjured control subjects (mean =  0.203, 
median =  0.216; vs. mean =  0.038, median =  0.010, respec-
tively). The GFAP levels of the TBI patients were consistently 
higher compared to the controls within studies. Those with 
CT-positive TBIs (adult: range of means = 0.00677–2.86 ng/mL, 
range of medians  =  0.1–1.9  ng/mL; pediatric: range of 
medians  =  0.73–1.19  ng/mL) had higher GFAP levels than 
CT-negative cases (adult: range of means = 0.00007–0.26 ng/mL, 
range of medians = 0.0078–0.33 ng/mL; and pediatric: range of 
medians = 0.18–1.25 ng/mL). Figure 2 summarizes the mean/
median GFAP findings of the individual studies.
Twenty-four (89%) studies reported a positive association 
between the GFAP level and traumatic lesions seen on head CT. 
taBLe 1 | Summary of study results.
controls tBi
Reference method 
(GFaP)
Lower level 
of detection 
(ng/mL)
N, type age, years male (%) GFaP level,  
ng/mL
N, severity age, years male (%) time of blood  
sampling  
(h after injury)
ct-positive, 
GFaP level, 
ng/mL
ct-negative, 
GFaP level, 
ng/mL
acute traumatic 
lesions on head 
ct, n (%)
GFaP 
related to 
lesions
extracranial 
injuries 
accounted for
adult studies, mostly mtBi
Bogoslovsky 
et al. (28)
Quanterix 
Corporation
0.0008 n = 69, 
healthy 
volunteers
Md = 45, 
IQR = 31–52
n = 35 
(51%)
Md = 0.0008, 
IQR = 0.0008–
0.00107
n = 34, 
mild-severe
Md = 39, 
IQR = 23–52
n = 29 
(85%)
Admission, ≤22 Md = 0.0176, 
IQR = 0.00388–
0.1296
N/A n = 34 (100%) Yes No
Study design, setting, country, and number of sites; study year(s): case–control; trauma center; USA, eight sites; 2007–2011
Main findings: CT-positive TBIs had significantly higher GFAP levels than controls. GFAP was able to discriminate CT-positive TBIs from controls
AU-ROC: 0.94 (CT+ vs. controls); cutoff: N/A
Buonora  
et al. (29)
Meso Scale 
discovery
0.21 n = 74, 
healthy 
volunteers
M = 47, 
SD = 19
n = 15 
(30%)
<0.3 n = 260, 
mild-severe
Mild-moderate: 
M = 47,  
SD = 19, 
moderate-severe: 
M = 47,  
SD = 21
n = 188 
(72%)
At admission, no 
details provided
N/A N/A n = 132 (51%) No Yes
Study design, setting, country, and number of sites; study year(s): case–control; trauma center; USA, two sites; Canada, four sites; N/A
Main findings: no relation between GFAP and CT findings in the cohort with mild-moderate TBI. Higher levels of GFAP in moderate-severe TBI patients compared to controls
AU-ROC: N/A; cutoff: N/A
Diaz-Arrastia 
et al. (19)a
Banyan 
biomarkers
0.1 n = 175, 
healthy 
volunteers
M = 34, 
SD = 14
n = 93 
(53%)
N/A n = 206, 
mild-severe
M = 42,  
SD = 18
n = 150 
(73%)
M = 10.9, 
SD = 6.4, 
min = 0.5, 
max = 24.3
N/A N/A n = 106 (51%) Yes No
Study design, setting, country, and number of sites; study year(s): case–control; trauma center; USA, three sites; N/A
Main findings: GFAP was able to discriminate: (i) CT-positive TBIs from CT-negative TBIs and (ii) TBIs from controls.
AU-ROC: 0.88 (CT+ vs. CT−) and 0.91 (TBI vs. controls); cutoff: N/A
Honda  
et al. (15)
BioVendor 0.1 N/A N/A N/A N/A n = 34, 
mild-severe
CT-positives: 
Md = 72, 
IQR = 54–85; 
CT-negatives: 
Md = 41, 
IQR = 30–59
n = 22 
(65%)
At admission, ≤3 N/A N/A n = 18 (53%) Yes No
Study design, setting, country, and number of sites; study year(s): cohort; trauma center, Japan, one site; 2006–2007
Main findings: GFAP was able to discriminate CT-positive TBIs from CT-negative TBIs.
AU-ROC: 0.98 (CT+ vs. CT−); cutoff: N/A
Lumpkins 
et al. (30)
BioVendor N/A N/A N/A N/A N/A n = 51, 
mild-severe
M = 43,  
SD = 21
n = 37 
(73%)
At admission, no 
details provided
M = 0.00677, 
SD = 0.01005
M = 0.00007, 
SD = 0.00018
n = 39 (76%) Yes Yes
Study design, setting, country, and number of sites; study year(s): cohort; trauma center, USA, one site; 2005–2006
Main findings: CT-positive TBIs had significantly higher GFAP levels than CT-negative TBIs. GFAP could discriminate CT-positive TBIs from CT-negative TBIs. Also, patients with surgical CT lesions had significantly higher GFAP levels than 
patients with diffuse lesions.
AU-ROC: 0.90 (CT+ vs. CT−); cutoff: 0.001 ng/mL, sensitivity = 62%, specificity = 100%
McMahon 
et al. (20)a
Banyan 
Biomarkers
0.01 N/A N/A N/A N/A n = 215, 
mild-severe
M = 42,  
SD = 18
n = 156 
(73%)
At admission, 
≤24
M = 2.86, 
SD = 3.74
M = 0.26, 
SD = 0.4
n = 110 (51%) Yes Yes
Study design, setting, country, and number of sites; study year(s): cohort; trauma center, USA, one site; N/A
Main findings: CT-positive TBIs had significantly higher GFAP levels than CT-negative TBIs. GFAP could discriminate CT-positive TBIs from CT-negative TBIs.
AU-ROC: 0.87 (CT+ vs. CT−); cutoff: 1.66 ng/mL, sensitivity = 45%, specificity = 99%, Brier score = 0.29
Metting  
et al. (31)
BioVendor 0.045 N/A N/A N/A N/A n = 94, mild M = 34.3, 
SD = 13.9 
N/A M = 2.4, 
SD = 2.1
M = 1.20, 
SD = 1.65
M = 0.05, 
SD = 0.17
n = 19 (20%) Yes Yes
Study design, setting, country, and number of sites; study year(s): cohort; University hospital, The Netherlands, one site; 2005–2007
Main Findings: CT-positive TBIs had significantly higher GFAP levels than CT-negative TBIs
AU-ROC: N/A; cutoff: N/A
(Continued )
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controls tBi
Reference method 
(GFaP)
Lower level 
of detection 
(ng/mL)
N, type age, years male (%) GFaP level,  
ng/mL
N, severity age, years male (%) time of blood  
sampling  
(h after injury)
ct-positive, 
GFaP level, 
ng/mL
ct-negative, 
GFaP level, 
ng/mL
acute traumatic 
lesions on head 
ct, n (%)
GFaP 
related to 
lesions
extracranial 
injuries 
accounted for
Okonkwo  
et al. (18)a
Banyan 
Biomarkers
0.1 N/A N/A N/A N/A n = 215, 
mild-severe
M = 42,  
SD = 18
n = 157 
(73%)
M = 10.9, 
SD = 6.4, 
min = 0.5, 
max = 23.4
M = 2.86, 
SD = 3.74
M = 0.26, 
SD = 0.41
n = 109 (51%) Yes No
Study design, setting, country, and number of sites; study year(s): cohort; trauma center, USA, three sites; N/A
Main Findings: GFAP was able to discriminate CT-positive TBIs from CT-negative TBIs
AU-ROC: 0.88 (CT+ vs. CT−); cutoff: 0.68 ng/mL, sensitivity = 73%, specificity = 89%, positive predictive value = 87%
Papa  
et al. (16)d
Banyan 
Biomarkers
0.000008 n = 188, 
non-TBI 
trauma 
controls
M = 40, 
SD = 16
n = 103 
(55%)
N/A n = 209, 
mild-moderate
M = 40,  
SD = 16
n = 131 
(63%)
M = 3.1, 95% 
CI = 3.0–3.3
N/A N/A n = 20 (10%) Yes Yes
Study design, setting, country, and number of sites; study year(s): case–control; trauma center, USA, one site; N/A
Main Findings: GFAP was able to discriminate CT-positive TBIs from CT-negative TBIs
AU-ROC: 0.84 (CT+ vs. CT−); cutoff: 0.067 ng/mL, sensitivity = 100%, specificity = 55%, negative predictive value = 100%, positive predictive value = 20%
Papa  
et al. (32)
Banyan 
Biomarkers
0.02 n = 199, 
no injuries 
and 
trauma 
controls
No injuries: 
M = 37, 
SD = 14; 
trauma 
controls: 
M = 44, 
SD = 17
n = 109 
(55%) (no 
injuries: 
n = 93; 
53%; 
trauma 
controls: 
n = 16; 
70%)
M = 0.057, 
95% 
CI = 0.044–
0.071
n = 108, 
mild-moderate
M = 39,  
SD = 15
n = 70 
(65%)
M = 2.6, 95% 
CI = 2.4–2.9
N/A N/A n = 32 (30%) Yes No
Study design, setting, country, and number of sites; study year(s): case–control; Trauma center, USA, 3 sites; N/A
Main findings: GFAP could discriminate CT-positive TBIs from CT-negative TBIs. GFAP was more reliable in discriminating: (i) TBIs from controls and (ii) TBIs with surgical CT lesions from non-surgical lesions
AU-ROC: 0.79 (CT+ vs. CT−) and 0.90 (TBI vs. controls); cutoff: 0.035 ng/mL, sensitivity = 97%, specificity = 18%, negative predictive value = 94%
Papa  
et al. (23)
Banyan 
Biomarkers
0.008 n = 259, 
trauma 
controls
M = 41, 
SD = 16, 
range = 18–83
n = 150 
(58%)
Md = 0.008, 
IQR = 0.008–
0.030; 
range = 0.008–
0.773
n = 325, 
mild-moderate
M = 39,  
SD = 16, 
range = 18–78
n = 212 
(65%)
M = 3.0, 
SD = 0.9
Md = 0.588, 
IQR = 0.140–
2.014, 
range = 0.008–
8.078
Md = 0.033, 
IQR = 0.008–
0.189, 
range = 0.008–
7.785
n = 35 (11%) Yes No
Study design, setting, country, and number of sites; study year(s): case–control; trauma center, USA, one site; 2010–2004
Main findings: CT-positive TBIs had significantly higher GFAP levels than CT-negative TBIs. GFAP could discriminate CT-positive TBIs from CT-negative TBIs
AU-ROC: 0.86 (CT+ vs. CT−); cutoff: N/A
Posti  
et al. (21)
The Evidence 
Investigator 
Cerebral 
Custom  
Array IV
N/A n = 81, 
orthopedic 
controls
M = 44.9, 
SD = 18.8
n = 35 
(43%)
N/A n = 324, 
mild-severe
M = 45.3, 
SD = 19.2
n = 238 
(74%)
At admission, 
<24
N/A N/A n = 200 (69%) Yes No
Study design, setting, country, and number of sites; study year(s): cohort; University hospital; Finland, one site; the United Kingdom, one site; 2011–2003
Main findings: CT-positive TBIs had significantly higher GFAP levels than CT-negative TBIs. GFAP could discriminate CT-positive TBIs from CT-negative TBIs. Also, GFAP levels were significantly higher in patients with mass lesions than with 
non-mass lesions
AU-ROC: 0.74 (CT+ vs. CT−); cutoff: N/A
Shehab  
and Nassar 
(33)
ELISA assay, 
not otherwise 
specified
N/A n = 20, 
healthy 
volunteers
N/A N/A M = 0.0015, 
SD = 0.00037
n = 70, 
mild-severe
M = 40.8,  
SD = 8, 
range = 22–64
n = 52 
(74%)
At admission,  
no details 
available
M = 0.1029, 
SD = 0.0471
M = 0.0668, 
SD = 0.0224
n = 43 (61%) Yes Yes
Study design, setting, country, and number of sites; study year(s): case–control; University hospital, Egypt, one site; N/A
Main findings: CT-positive TBIs had significantly higher GFAP levels than CT-negative TBIs. Also, TBIs had significantly higher GFAP levels than controls
AU-ROC: N/A; cutoff: N/A
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controls tBi
Reference method 
(GFaP)
Lower level 
of detection 
(ng/mL)
N, type age, years male (%) GFaP level,  
ng/mL
N, severity age, years male (%) time of blood  
sampling  
(h after injury)
ct-positive, 
GFaP level, 
ng/mL
ct-negative, 
GFaP level, 
ng/mL
acute traumatic 
lesions on head 
ct, n (%)
GFaP 
related to 
lesions
extracranial 
injuries 
accounted for
Welch  
et al. (17)e
Banyan 
Biomarkers
0.02 N/A N/A N/A N/A n = 231, 
mild-moderate
M = 45.6, 
SD = 18.4
n = 151 
(60%)
At admission,  
≤6
Md = 0.1105, 
IQR = 0.0204–
0.4318
Md = 0.0078, 
IQR = 0.0027–
0.0221
n = 36 (14%) Yes No
Study design, setting, country, and number of sites; study year(s): cohort; trauma center; USA, five sites; Hungary, two sites; N/A
Main findings: GFAP could discriminate CT-positive TBIs from CT-negative TBIs
AU-ROC: 0.79 (CT+ vs. CT−); cutoff: 0.015 ng/mL, sensitivity = 81%, specificity = 67%
Welch  
et al. (22)e
Banyan 
Biomarkers
0.02 N/A N/A N/A N/A n = 167, 
mild-moderate
M = 46.0, 
SD = 17.8
n = 102 
(61%)
Multiple time 
points: 0–6, 
>6–12, >12–18, 
and >18–24 h
Md = 0.122, 
IQR = 0.020–
0.437
Md = 0.010, 
IQR = 0.004–
0.031
n = 33 (20%) Yes No
Study design, setting, country, and number of sites; study year(s): cohort; trauma center; USA, five sites; Hungary, two sites; N/A
Main findings: GFAP could discriminate CT-positive TBIs from CT-negative TBIs
AU-ROC: 0.84–0.94 (CT+ vs. CT−); cutoff: N/A
adult studies, moderate and severe tBi
Lei  
et al. (34)
BioVendor 0.045 n = 135, 
healthy 
blood 
donors
M = 39.2, 
SD = 15.3, 
range = 18–65
n = 88 
(65%)
Md = 0, 
IQR = 0–0, 
range = 0.048–
0.076
n = 67, severe M = 37.2, 
SD = 14.3
n = 51 
(76%)
At admission, ≤4 Md = 1.924, 
IQR = 0.891–
3.126
N/A n = 64 (100%) Yes No
Study design, setting, country, and number of sites; study year(s): case–control; trauma center, China, one site; 2011–2004
Main findings: TBIs had significantly higher GFAP levels than controls. Also, patients with surgical CT lesions had significantly higher GFAP levels than patients with diffuse lesions
AU-ROC: N/A; cutoff: N/A
Mondello  
et al. (35)f
BioVendor N/A n = 167, 
healthy 
blood 
donors
M = 36.9, 
SD = 14.1
n = 95 
(57%)
M = 0.07, 
SD = 0.03
n = 81,  
severe
M = 47.9, 
SD = 20.4
n = 65 
(80%)
At admission,  
no details 
provided
N/A N/A n = 80 (99%) Yes Yes
Study design, setting, country, and number of sites; study year(s): case–control; trauma center; USA, two sites; Hungary, two sites; N/A
Main findings: TBIs had significantly higher GFAP levels than controls. Also, patients with mass lesions on CT had significantly higher GFAP levels than patients with diffuse lesions
AU-ROC: N/A; cutoff: N/A
Mondello  
et al. (36)f
BioVendor N/A N/A N/A N/A N/A n = 59,  
severe
M = 46.7, 
range = 19–89
n = 46 
(78%)
M = 9,  
SEM = 1
N/A N/A n = 58 (98%) Yes No
Study design, setting, country, and number of sites; study year(s): cohort; trauma center; USA, two sites; Hungary, two sites; N/A
Main findings: TBI patients with mass lesions on CT had significantly higher GFAP levels than patients with diffuse lesions. GFAP was able to discriminate TBIs with mass lesions from TBIs with diffuse lesions
AU-ROC: 0.72 (mass lesions vs. diffuse lesions); cutoff: N/A
Pelinka  
et al. (37)b
LIAISON®  
GFAP and 
S100B assay
0.03 N/A N/A N/A N/A n = 92, 
moderate-
severe
Md = 39, 
IQR = 28–55
n = 67 
(73%)
At admission,  
<12
N/A N/A n = 92 (100%) Yes No
Study design, setting, country, and number of sites; study year(s): cohort; trauma center, Austria, three sites; 1999–2002
Main Findings: GFAP levels were positively related to the severity of traumatic CT findings (Marshall grade)
AU-ROC: N/A; cutoff: N/A
Pelinka  
et al. (38)b
LIAISON®  
GFAP and 
S100B assay
0.03 n = 13, 
polytrauma 
patients
Md = 39, 
IQR = 28–48
n = 7 
(54%)
N/A n = 101, 
moderate-
severe
Md = 39, 
IQR = 27–55
n = 76 
(75%)
At admission,  
<12
N/A N/A n = 101 (100%) Yes No
Study design, setting, country, and number of sites; study year(s): case–control; trauma center, Austria, three sites; 1999–2003
Main findings: GFAP levels were positively related to the severity of traumatic CT findings (Marshall grade)
AU-ROC: N/A; cutoff: N/A
taBLe 1 | Continued
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controls tBi
Reference method 
(GFaP)
Lower level 
of detection 
(ng/mL)
N, type age, years male (%) GFaP level,  
ng/mL
N, severity age, years male (%) time of blood  
sampling  
(h after injury)
ct-positive, 
GFaP level, 
ng/mL
ct-negative, 
GFaP level, 
ng/mL
acute traumatic 
lesions on head 
ct, n (%)
GFaP 
related to 
lesions
extracranial 
injuries 
accounted for
Vos  
et al. (39)
Future 
diagnostics
N/A N/A N/A N/A N/A n = 79, 
moderate-
severe
M = 47.0, 
range = 18–91
n = 57 
(72%)
Md = 1, 
IQR = 0.5–5
Md = 0.1–2.17 Md = 0.02, 
95% 
CI = 0.02–1
n = 64 (84%) Yes No
Study design, setting, country, and number of sites; study year(s): cohort; trauma center, The Netherlands, one site; 2004–2006
Main findings: GFAP levels were significantly related to the severity of traumatic CT findings (Marshall grade)
AU-ROC: N/A; cutoff: N/A
Vos  
et al. (40)
ELISA assay, 
not otherwise 
specified
N/A N/A N/A N/A N/A n = 85,  
severe
Md = 32, 
range = 15–81
n = 61 
(72%)
Md = 2.5, 
range = 0.25–30
N/A N/A n = 82 (96%) Yes No
Study design, setting, country, and number of sites; study year(s): Cohort; University hospital, The Netherlands, one site, 1999–2000
Main findings: GFAP levels were significantly related to the severity of traumatic CT findings (Marshall grade)
AU-ROC: N/A; cutoff: N/A
Pediatric studies
Fraser  
et al. (41)
Ridascreen  
Risk Material 
10/5
N/A N/A N/A N/A N/A n = 27,  
severe
M = 10.6, 
SD 0.9, 
range = 2.4–17
n = 14 
(52%)
At admission,  
no details 
available
N/A N/A n = 27 (100%) No Yes
Study design, setting, country, and number of sites; study year(s): cohort; pediatric intensive care unit, Canada, four sites; N/A
Main findings: only severe CT-positive TBI cases included in the study. GFAP failed to correlate with traumatic CT abnormalities
AU-ROC: N/A; cutoff: N/A
Mondello  
et al. (42)
Meso Scale 
Discovery
N/A n = 40, 
patients 
treated 
for trivial 
reason 
other 
than head 
injury
M = 3.9, 
SD = 3.8
n = 23 
(58%)
Md = 0.01, 
IQR = 0.00–0.05
n = 45, 
mild-severe
M = 3.8,  
SD = 3.8
n = 28 
(62%)
Md = 4.7, 
range = 0.5–20.6
Md = 0.73, 
IQR = 0.15–2.28
Md = 0.21, 
IQR = 0.08–
1.37
n = 29 (64%) Yes No
Study design, setting, country, and number of sites; study year(s): case–control; trauma center, USA, one site; N/A
Main findings: CT-positive TBIs had significantly higher GFAP levels than controls. GFAP could discriminate mild TBIs from controls. However, GFAP could not discriminate between CT-positive and CT-negative TBIs
AU-ROC: 0.81 (mild TBI vs. control); cutoff: N/A
Zurek and 
Fedora (43)
BioVendor N/A N/A N/A N/A N/A n = 59, severe M = 8.9 n = 36 
(61%)
At admission, <3 N/A N/A N/A No No
Study design, setting, country, and number of sites; study year(s): cohort; University hospital, The Czech Republic, one site; 2007–2009
Main findings: GFAP failed to correlate with traumatic CT abnormalities
AU-ROC: N/A; cutoff: N/A
Papa  
et al. (44)c
Banyan 
Biomarkers
0.000008 n = 60, 
non-TBI 
trauma 
controls
M = 12,  
SD = 6, 
range = 0.1–
21
n = 39 
(65%)
Md = 0.03, 
IQR = 0.01–0.05
n = 197, 
mild-moderate
M = 11.5,  
SD = 7, 
range = 0.1–21
n = 131 
(66%)
M = 3.3, 95% 
CI = 3.1–3.5
Md = 1.01, 
95% 
CI = 0.59–1.48
Md = 0.18, 
95% 
CI = 0.06–
0.47
n = 18 (12%) Yes No
Study design, setting, country, and number of sites; study year(s): case–control; trauma center, USA, three sites; N/A
Main findings: CT-positive TBIs had significantly higher GFAP levels than CT-negative TBIs. GFAP could discriminate CT-positive TBIs from CT-negative TBIs
AU-ROC: 0.82 (CT+ vs. CT−); cutoff: 0.15 ng/mL, sensitivity = 94%, specificity = 47%, negative prediction value = 98%
taBLe 1 | Continued
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controls tBi
Reference method 
(GFaP)
Lower level 
of detection 
(ng/mL)
N, type age, years male (%) GFaP level,  
ng/mL
N, severity age, years male (%) time of blood  
sampling  
(h after injury)
ct-positive, 
GFaP level, 
ng/mL
ct-negative, 
GFaP level, 
ng/mL
acute traumatic 
lesions on head 
ct, n (%)
GFaP 
related to 
lesions
extracranial 
injuries 
accounted for
Papa  
et al. (45)c
Banyan 
Biomarkers
0.000008 n = 42, 
non-TBI 
orthopedic 
trauma 
controls
M = 13,  
SD = 5
n = 24 
(59%)
Md = 0.03, 
IQR = 0.01–0.06
n = 114, 
mild-moderate
M = 13,  
SD = 7
n = 76 
(67%)
At admission, 
<6 h
Md = 1.19, 
IQR = 0.78–5.13
Md = 0.25, 
IQR = 0.10–
0.63
n = 8 (9%) Yes No
Study design, setting, country, and number of sites; study year(s): case–control; trauma center, USA, three sites; N/A
Main findings: head injury patients had significantly higher GFAP levels than controls. GFAP could discriminate CT-positive TBIs from CT-negative TBIs
AU-ROC: 0.85 (CT+ vs. CT−); cutoff: 0.15 ng/mL, sensitivity = 100%, specificity = 36%, likelihood ratio = 1.6
M, mean; Md, median; GFAP, glial fibrillary acidic protein; GFAP-BDP, glial fibrillary acidic protein breakdown product; CT, computed tomography; CDE, common data elements; AU-ROC, area under the receiver operating curve; IQR, 
interquartile range; 95% CI, 95% confidence interval; TBI, traumatic brain injury; CT+, CT-positive (patients with acute traumatic intracranial lesions on head CT); CT−, CT-negative (patients with no acute traumatic intracranial lesions 
on head CT); cutoff, GFAP cutoff level for a trauma-positive head CT.
aTRACK-TBI; studies contain some overlapping cases, also GFAP-BDP levels were measured.
bMostly the same sample in both studies.
cPartly the same sample in both studies.
dGFAP-BDP levels were also measured.
eMostly the same sample in both studies.
fMostly the same BANDITS sample in both studies.
GFAP platforms:
1. Quanterix Corporation, Lexington, MA, USA (method:single molecule array).
2. Banyan Biomarkers, Alachua, FL, USA [method: enzyme-linked immunosorbent assay (ELISA)].
3. BioVendor, Brno, Czech Republic; Candler, NC, USA; and Heidelberg, Germany (method: ELISA).
4. The Evidence Investigator Cerebral Custom Array IV Randox Laboratories Ltd., Crumlin, County Antrim, United Kingdom (method: digital immonoassay technology).
5. Meso Scale Discovery, Gaithersburg, MD, USA (method: electro-chemiluminescent immunoassay).
6. LIAISON® GFAP and S100B assay, AB Sangtec Medical, Bromma, Sweden (method: monoclonal immunoluminometric assay).
7. Future diagnostics, Wijchen, the Netherlands (method: 2-site luminometric immunoassay).
8. Ridascreen Risk Material 10/5, R-Biopharm AG, Darmstadt, Germany (method: ELISA).
taBLe 1 | Continued
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FiGURe 2 | Serum glial fibrillary acidic protein (GFAP) findings (means and medians) from individual studies stratified into different subgroups: (i) controls,  
(ii) CT-negative traumatic brain injury (TBI) (TBI CT−), and (iii) CT-positive TBIs (TBI CT+). For comparison, the findings are subdivided into adult and pediatric 
subpopulations, and also results of the most commonly used Banyan Biomarkers (Banyan Biomarkers, Inc., Alachua, FL, USA) assay are presented separately.
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Higher GFAP levels were related to lesion severity in the major-
ity of studies that examined lesion severity (21, 30, 32, 34–36). 
Additionally, mass lesions and surgically treated lesions were 
associated with higher GFAP levels than diffuse lesions in all 
five studies where this comparison was made (21, 30, 32, 35, 36). 
Thirteen studies reported receiver operating curves on how well 
GFAP was able to discriminate between head trauma patients 
with positive vs. negative CT scans. The areas under the receiver 
operating curves varied between 0.74 and 0.98. Eight studies 
reported binary classification (CT-positive vs. CT-negative) test 
results for GFAP (Table 1). Six adult (16–18, 20, 30, 32) and two 
pediatric (44, 45) studies examined the sensitivity of GFAP cutoff 
values for identifying intracranial lesions. A pediatric GFAP 
cutoff value (0.15  mg/mL) was derived from these two studies 
(44, 45) although it should be noted that the two studies were 
comprised of a partially overlapping sample. The adult GFAP 
cutoff values were more inconsistent than the pediatric ones and 
ranged between 0.001 and 1.66  ng/mL. One adult study (16) 
established a GFAP cutoff value of 0.067 ng/mL with a sensitivity 
of 100% and a specificity of 55%.
Level of evidence and Risk of Bias
No study was excluded from the review due to a significant 
source of bias. The Newcastle–Ottawa Scale and the level of 
evidence (the Oxford Center of Evidence-based Medicine) results 
are presented in Table  2. The mean level of evidence was 3.6 
(17 studies classified as level 4 and 10 studies classified as level 3). 
On the Newcastle-Ottawa Scale, the average ratings for the 27 
studies were as follows: selection (0–4)  =  2.9, comparability 
(0–2) = 1.0, and outcome (0–3) = 3.0. The GRADE ranking for 
the level of evidence was C. The rating was based on observa-
tional studies with fairly consistent results. However, the level 
of evidence was downgraded, because of partly incomplete data 
reporting, and the absence of effect estimates.
Findings of Studies examining  
mostly mild tBi
Screening for possible CT-positive trauma-related intracranial 
lesions is clinically relevant among those with mild head trauma 
because many of these injuries could be managed without CT 
imaging. Therefore, the findings of studies examining mostly 
mild TBI are summarized separately. There were 15 adult studies 
(15–23, 28–33) and 3 pediatric studies (42, 44, 45) that included 
mostly subjects with mild TBIs, although the samples tended to 
be heterogeneous and included some patients with moderate or 
severe TBIs, too. Additionally, the operational criteria for mild 
TBI were not homogenous among the included studies that 
examined mostly mild TBIs. This methodological heterogene-
ity hindered the possibility of organizing and summarizing the 
results in a combined manner. The research designs were not 
taBLe 2 | The Newcastle–Ottawa Scale scores and the level of evidence of the included studies.
Newcastle–Ottawa Scale center of evidence-based medicine
Reference Selection (0–4) comparability (0–2) Outcome (0–3) Level of evidence (1–5)
adult
Bogoslovsky et al. (28) ⋆⋆⋆ ⋆ ⋆⋆⋆ 4
Buonora et al. (29) ⋆⋆⋆ ⋆ ⋆⋆ 4
Diaz-Arrastia et al. (19) ⋆⋆⋆ ⋆⋆ ⋆⋆⋆ 4
Honda et al. (15) ⋆⋆⋆ ⋆ ⋆⋆⋆ 4
Lei et al. (34) ⋆⋆⋆ ⋆ ⋆⋆⋆ 4
Lumpkins et al. (30) ⋆⋆⋆ ⋆⋆ ⋆⋆⋆ 4
McMahon et al. (20) ⋆⋆⋆ ⋆ ⋆⋆⋆ 3
Mondello et al. (35) ⋆⋆⋆ ⋆ ⋆⋆⋆ 4
Mondello et al. (36) ⋆⋆⋆ ⋆⋆⋆ 4
Metting et al. (31) ⋆⋆⋆ ⋆ ⋆⋆⋆ 3
Okonkwo et al. (18) ⋆⋆⋆ ⋆⋆ ⋆⋆⋆ 3
Papa et al. (16) ⋆⋆⋆⋆ ⋆ ⋆⋆⋆ 3
Papa et al. (32) ⋆⋆⋆⋆ ⋆⋆ ⋆⋆⋆ 3
Papa et al. (45) ⋆⋆⋆ ⋆⋆ ⋆⋆⋆ 3
Pelinka et al. (37) ⋆⋆ ⋆⋆⋆ 4
Pelinka et al. (38) ⋆⋆ ⋆⋆⋆ 4
Posti et al. (21) ⋆⋆⋆ ⋆⋆⋆ 4
Shehab and Nassar (33) ⋆⋆ ⋆⋆⋆ 4
Welch et al. (17) ⋆⋆⋆ ⋆⋆⋆ 4
Welch et al. (22) ⋆⋆⋆⋆ ⋆⋆ ⋆⋆⋆ 3
Vos et al. (39) ⋆⋆⋆ ⋆⋆⋆ 4
Vos et al. (40) ⋆⋆⋆ ⋆⋆⋆ 4
Pediatric
Fraser et al. (41) ⋆⋆ ⋆⋆⋆ 4
Mondello et al. (42) ⋆⋆⋆ ⋆⋆ ⋆⋆⋆ 3
Zurek and Fedora (43) ⋆⋆⋆ ⋆⋆⋆ 4
Papa et al. (44) ⋆⋆⋆ ⋆⋆ ⋆⋆⋆ 3
Papa et al. (23) ⋆⋆⋆ ⋆⋆ ⋆⋆⋆ 3
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diagnostic studies of consecutive cohorts of “mild head trauma” 
cases that employed GFAP as the experimental diagnostic test for 
intracranial abnormalities compared to a CT or MRI gold stand-
ard. Of the included studies, 10 (56%) were case–control and 8 
(44%) cohort studies. A total of 2,899 participants were enrolled 
in the studies with individual study sample sizes varying between 
34 and 325 [adults: n = 2,543 (88%); pediatric: n = 356 (12%)]. 
Control sample sizes varied between 20 and 259 participants, 
for a total of 1,207 [adults: n = 1,065 (88%); pediatric: n = 142 
(12%)]. Orthopedic trauma patients and healthy volunteers were 
the most commonly enrolled controls; other controls included 
patients treated for trivial reason other than head injury. Six dif-
ferent analytical platforms were employed across the 18 studies. 
The sandwich ELISA manufactured by Banyan Biomarkers was 
the most frequently used platform (10 studies, 56%). There was 
considerable variability in GFAP levels within the same platform, 
within the same analytic method, and between platforms and this 
was irrespective of the studied patient and cohort type. Seventeen 
(94%) of those studies reported a positive association between 
the GFAP level and the head CT trauma lesions. A considerable 
number of studies did not explicitly specify the subtypes of 
abnormalities that were considered as acute traumatic CT lesions 
(n = 6, 33%). Twelve (67%) studies reported receiver operating 
curves on how well GFAP discriminated CT-positive TBI patients 
from CT-negative ones. The areas under the receiver operating 
curves varied between 0.74 and 0.98. Eight (44%) studies reported 
binary classification (CT-positive vs. CT-negative) test results for 
GFAP. Six adult (16–18, 20, 30, 32) and two pediatric (44, 45) 
studies examined GFAP cutoff values for head CT positivity. The 
mean level of evidence was 3.4 (8 studies classified as level 4 and 
10 studies classified as level 3). On the Newcastle–Ottawa Scale, 
the average ratings for the 18 studies were as follows: selection 
(0–4) = 3.0, comparability (0–2) = 1.3, and outcome (0–3) = 2.9. 
The GRADE ranking for the level of evidence was C.
DiScUSSiON
Summary of main Findings
Blood levels of GFAP were associated with acute traumatic 
lesions on head CT. GFAP levels usually were associated with the 
CT-detectible lesion severity (15–23, 28, 30–40, 42, 44, 45), with 
surgical lesions (i.e., mass-occupying hematomas/contusions 
requiring craniotomy) generally showing the highest elevations 
of serum GFAP (21, 30, 32, 34–36). These findings were consistent 
across the age spectrum. Based on our review, GFAP holds prom-
ise as a potential screening test for acute CT-detectible traumatic 
brain lesions. However, clearly defined cutoff values (CT-negative 
vs. CT-positive) for specific GFAP platforms have not been estab-
lished. The literature has significant methodological limitations 
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that do not allow us to determine the sensitivity or specificity of 
GFAP for identifying any CT abnormality, or clinically important 
CT abnormalities, following mild TBI. Well-designed diagnostic 
test studies for GFAP are needed.
Findings in Pediatric Samples
Children were the focus of interest in five studies (41–45). Out 
of these five studies only three investigated serum GFAP levels 
in relation to CT-negative and CT-positive TBIs (42, 44, 45). 
In these three pediatric studies, the results were in line with the 
adult findings. However, the small number of pediatric stud-
ies casts some doubt on the generalizability and applicability 
of these findings. Comparisons between adults and pediatric 
posttraumatic serum GFAP dynamics have not yet been done 
to our knowledge. However, normal GFAP levels of healthy 
children are most likely lower than those of healthy adults in 
the cerebrospinal fluid (48). In our review, the distribution of 
GFAP concentrations among adult TBI patients differed some-
what from the pediatric counterparts. The pediatric values were 
more consistent and the measured range was narrower than 
with adults (see Table 1; Figure 2). One reason for this is that 
only two different analytical platforms were used in the positive 
pediatric studies. In the light of the current evidence, we cannot 
extrapolate meaningfully as to other factors that account for the 
difference in adult and pediatric GFAP levels.
Negative Findings
Three (29, 41, 43) out of the 27 studies did not find any relation 
between acute (≤24  h post-injury) serum GFAP levels and 
traumatic head CT findings. Two (41, 43) of these negative stud-
ies consisted of pediatric patients with severe TBI. In the first 
study, Fraser et  al. (41) examined whether arterial GFAP was 
related to traumatic lesions in a sample exclusively consisting of 
CT-positive severe TBIs. In the second study, Zurek and Fedora 
(43) compared different Marshall score grades to serum GFAP 
(Marshall grade distributions not available) and found no rela-
tion between GFAP level and Marshall grades. These two negative 
pediatric studies did not examine GFAP levels in relation to head 
CT positivity and negativity. They only considered CT-positive 
cases. Furthermore, among severe TBIs the identification of 
intracranial traumatic lesions with serum GFAP is not clinically 
relevant because these patients always require an emergency head 
CT as part of their routine management. In the only negative adult 
study, Buonora and co-authors (29) did not find an association 
between CT-detectible intracranial trauma lesions and GFAP in 
a case–control study consisting of mild to severe TBIs. The null 
finding was likely because most of the GFAP levels were below 
the lower limit of quantification (0.27  ng/mL) and detection 
(0.21 ng/mL) for their assay. The lower limits of quantification 
and detection of Buonora’s study were multiple times higher than 
in other studies.
methodological considerations
We were not able to extrapolate cutoff values or percent increases 
in GFAP that consistently predict intracranial pathology based 
on the data presented in the articles. There was considerable 
variability in measured GFAP levels that was likely related to 
the analytic GFAP platform employed. Considerable variability 
in GFAP levels between studies employing the same GFAP 
platforms was also apparent not only in the TBI groups, but in 
the orthopedically injured and even within the normal healthy 
control samples. Time after injury may also be a confounding 
factor. GFAP was measured from as early as 15  min (40) and 
as late as to 24  h after TBI within individual studies. GFAP 
temporal dynamics were examined by only two studies (22, 23). 
In one study, patients with a positive head CT showed an average 
GFAP elevation of 3.7% per hour over the first 24 h compared 
to head trauma cases with negative CTs (22). In the other study, 
serum GFAP levels were reported to peak 20 h after TBI among 
those with intracranial lesions detected on CT, and slowly decline 
over 72 h following injury (23). In most of the included studies, 
a detailed methodology of sample processing was not reported. 
This hinders the ability to compare possible factors affecting the 
GFAP results. In two studies, blood samples were taken from an 
arterial line and no specific GFAP levels were reported. Whether 
arterial and venous GFAP levels are comparable is unknown.
Common Data Elements (CDEs) aid in harmonizing neuro-
imaging data across studies and sites (49). In the studies included 
in our review, very few utilized the National Institute of Health’s 
CDEs and explicitly defined which lesions were designated 
as traumatic. Half of the studies used the Marshall grading to 
classify head CT findings (15, 21, 28, 31, 34–40, 43). Overall, 
the studies did not clearly define which intracranial lesions 
were ascertained as acute TBI abnormalities. For example, some 
studies [e.g., Mondello et al. (42)] considered skull fractures as 
an acute traumatic intracranial finding, whereas other studies 
excluded these lesions. Along with possible discrepancies in 
trauma lesion interpretation, the technical details of head CT 
imaging were poorly described. The applied slice thickness and 
image orientations (sagittal, axial, and coronal) were almost 
universally lacking. Furthermore, the interpreter (e.g., on call 
radiologist, neuroradiologist, neurosurgeon) of the head CT 
images was not stated in the majority of studies. As defined in 
our inclusion criteria, head CT imaging was performed within 
24 h after injury in the included studies. In two studies (17, 43), 
neuroimaging was conducted within 6 h after injury. Hyperacute 
(initial hours after injury) imaging can result in false negative 
scans; for example, some contusions do not demarcate well in the 
first few hours after trauma.
GFaP in the context of Other Diseases 
and Orthopedic injuries
Glial fibrillary acidic protein elevations are not specific to TBI; 
other acute, destructive central nervous system lesions will also 
raise levels—albeit modestly so. In an exploratory study of a 
broad spectrum of neurological diseases, GFAP levels were very 
low in most patients (50). Intracerebral hemorrhage, as a result 
of cerebrovascular disease, is associated with elevated levels of 
GFAP (51, 52). Furthermore, high-grade infiltrating tumors 
(53, 54) and demyelinating diseases [e.g., multiple sclerosis 
(55)] have also been shown to result in increased serum GFAP. 
Chronic neurological conditions (e.g., migraines and epilepsy), 
however, do not appear to influence GFAP levels to a degree that 
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would be expected to confound the usefulness of GFAP as a TBI 
biomarker (although there are few studies relating to chronic 
conditions) (50).
It has been reported that injuries outside the brain can also 
elevate serum GFAP concentrations (56). GFAP has been 
detected in non-glial and non-central nervous system cells, such 
as Schwann cells, chondrocytes, fibroblasts, myoepithelial cells, 
lymphocytes, and liver stellate cells. These can be a source of 
released GFAP after extremity and bodily trauma. Only a third of 
the studies accounted for concurrent orthopedic injuries among 
TBI patients (16, 20, 29–31, 33, 35, 41). The association between 
GFAP and head CT findings (i.e., CT-positives had higher GFAP 
levels than CT-negatives of non-head injured controls, and mass 
lesion were related to higher GFAP levels than diffuse lesions) 
was present in those studies involving patients with orthopedic 
injury. Only two adult studies (23, 32) and two pediatric studies 
(44, 45) reported GFAP levels of trauma controls (median = 0.008, 
median  =  0.03, and median  =  0.3  ng/mL, respectively). The 
pediatric orthopedic control values were derived from mostly the 
same control cohort. One study (32) examined both non-injured 
controls and trauma controls; orthopedic trauma seemed to 
increase acute GFAP levels (non-injured controls: mean = 0.038, 
95% CI = 0.029–0.047, median = 0.010, IQR = 0.050; vs. non-
TBI trauma controls: mean  =  0.203, 95% CI  =  0.048–0.357, 
median =  0.216, IQR =  0.275). To date, this is the only study 
that directly compares orthopedic injury subjects to non-injured 
controls. Based on this limited amount of available data, there 
appears to be an association between head trauma and GFAP 
levels in studies comparing to orthopedically injured samples, but 
we cannot draw any solid conclusions on the effects of orthopedic 
injury on serum GFAP levels.
Strengths and Limitations
Our review has several strengths. We applied a comprehensive 
literature search protocol to both the pediatric and adult litera-
ture. Gray literature was examined separately. The reference lists 
of all the eligible articles were screened for potential unidentified 
new articles. This screening identified no new eligible articles. 
The literature search protocol can, therefore, be considered 
inclusive.
There is a potential for publication bias in our conclusions 
because we only reviewed published articles; studies with nega-
tive findings are less likely to be published. Additionally, non- 
English publications were not included. Most importantly, we 
could not pool data across studies and meta-analyze GFAP 
levels. We were unable to conduct a quantitative analysis due to 
the methodological heterogeneity between studies (e.g., differ-
ences in inclusion criteria and reporting of CT findings, variance 
in GFAP levels among assays), and constraints in the reported 
principal summary measures (i.e., different measures of central 
tendency and variance were reported, and no effect sizes were 
reported). Although measures were taken to gather missing data, 
the amount of unattainable results was considerable (e.g., GFAP 
levels of CT-positive cases). The review included articles that 
utilized partially overlapping patient and/or control samples. 
Principal investigators of these studies were contacted to clarify 
the extent of sample overlap. Unfortunately, these investigator 
inquiries were only partially answered. It was very difficult to 
determine the association between GFAP levels and CT lesions 
in patients with mild TBIs because the research designs often 
included heterogeneous injury severity samples and diverse 
definitions of injury severity.
Another clinically important limitation of the overall litera-
ture is that the sensitivity of the different GFAP assays to epidural 
hematomas, and the temporal dynamics of GFAP in relation 
to the evolution of an epidural hematoma, is unknown. Some 
epidural hematomas, especially in the early stages of evolution, 
are associated with only mild or modest amounts of parenchymal 
brain injury—and the extent to which GFAP is elevated in those 
cases is not known.
classification of the Level of evidence
Based on the classification of the Oxford Center of Evidence-
Based Medicine (1 to 5), the level of evidence of the individual 
studies was 3 or 4 (average = 3.6). The GRADE ranking for the 
level of evidence is C. A major limitation in most studies was the 
use of a control group that may not have been representative of 
the case population. In general, the controls were derived from 
a completely different population than the cases and limited 
comparison was performed on the basic demographics (e.g., age, 
gender, prior health) of these groups (controls vs. TBIs). Case 
selection was also a point of concern because studies applied 
widely different inclusion and exclusion criteria. Additionally, 
very little data (i.e., age, gender, injury mechanism, injury sever-
ity, reason for exclusion) was given on the population screened for 
study inclusion. Thus, the extent to which the results generalize 
well to a broader population is unknown. The review consisted of 
studies conducted in multiple countries with different health-care 
systems. Nevertheless, the main finding that GFAP correlated 
with CT-detectible intracranial trauma lesions was consistent 
between these studies. It seems that the results are generalizable 
and applicable rather globally.
Future Directions
In the future, larger studies are needed to replicate, extend, and 
refine these findings. Current ongoing large-scale initiatives, 
CENTER-TBI (57), and TRACK-TBI (58), are important in 
verifying the potential of GFAP as a marker in acute TBI triage. 
From a practical point of view, a rapid capillary blood-based 
GFAP screening test would be of benefit for patient management 
in a pre-hospital environment (e.g., sideline assessment in sports 
and emergency medical services). What is lacking, and clearly 
needed, is an assay with clearly defined cutoff values for abnor-
mality that has excellent sensitivity and at least good specificity in 
multiple clinical groups, including those with orthopedic injuries 
and those with a wide range of pre-existing neurological and 
medical problems. It is common for people with pre-existing 
medical, neurological, and neurodegenerative diseases to present 
to the emergency department with head trauma. Diagnostic stud-
ies with clear GFAP cutoffs are needed before possible clinical 
implementation.
Future well-designed diagnostic studies of GFAP would 
examine the appropriate spectrum of patients (i.e., the group the 
test will be applied to in a real-world setting); carefully define the 
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“diagnosis” or condition of interest (e.g., a clinically important 
lesion on CT, any intracranial lesion on CT, or any traumatic 
lesion on MRI); apply the neuroimaging to all subjects; use 
independent or blind comparison with the imaging results; and 
present sensitivity, specificity, and likelihood ratios (and positive 
and negative predictive values if the prevalence of intracranial 
abnormalities in the sample studied is close to the prevalence of 
intracranial abnormalities in the population of interest). Future 
researchers should carefully describe their findings in a manner 
that allows physicians to determine if they can use the results in 
their work setting, whether the results apply to the patients that 
they see, and whether the results would actually change clinical 
practice (e.g., ordering fewer head CT scans). Future researchers 
are also encouraged to assemble and present case series involving 
epidural hematomas and carefully examine their GFAP levels and 
temporal dynamics.
conclusion
In conclusion, GFAP is predictive of CT-positive brain damage 
in acute head injuries. GFAP increases within hours following 
injury in peripheral blood. A limited number of studies suggest 
the elevation may peak at 20–24 h post-injury, and thus consid-
eration of temporal dynamics may improve diagnostic sensitivity 
and specificity. Although promising, at the present time there is 
not enough evidence to suggest that GFAP can be used clinically 
as a reliable discriminant of CT-positive and CT-negative brain 
injury. With future diagnostic research and refinements, GFAP 
may have the potential to be used as part of a comprehensive 
diagnostic algorithm to identify patients with intracranial 
abnormalities.
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